HAEMATO PHARM GmbH

HAEMATO PHARM GmbH specializes in the manufacture and sale of generics and EU original medicines. With its product portfolio, the company focuses on five major therapeutic areas: HIV / AIDS, Neurology, Oncology, Rheumatology and Urology.

HAEMATO MED GmbH

HAEMATO MED GmbH is an innovative healthcare company specializing in the development and commercialization of pharmaceutical, medical and medical devices for aesthetic surgery and cosmetic dermatology.

HAEMATO AG

HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of high-end specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market was started. HAEMATO AG assumes that first products will hit the market in the coming year, which has already created the basis for further growth and additional income.

News

We inform you about the current business development of HAEMATO AG and about our investor relations activities.
Ad-hoc disclosure under Art.17 MAR

Ad-hoc disclosure under Art.17 MAR

by | Jun 10, 2020 |

HAEMATO AG: Ad-hoc disclosure under Article 17 MAR HAEMATO AG: MPH Health Care AG brings its shares in HAEMATO AG to M1 Kliniken AG as part of a non-cash capital increase. Today MPH Health Care AG and M1 Kliniken AG informed us that MPH Health Care AG transfers all of...

read more
AGM postponement

AGM postponement

by | May 27, 2020 |

Due to the present imponderables HAEMATO AG will reschedule the Annual General Meeting originally intended on July 8, 2020 to a later date. Due to the current uncertainties around the COVID-19 pandemic the Executive Board and the Supervisory Board of HAEMATO AG,...

read more

Click here for more news

Publications

Get an overview of the current status and development of HAEMATO AG. Here you will find information on the current status of the Group and on developments in recent years.

Read the Reports

Financial data at a glance

Share Price

BUY: 6.00 €, 4 September 2019

BUY: 4.80 €, 9 September 2019

Values & Performance

Here you will find the financial figures of the HAEMATO Group in a clear tabular form.

Rating & Research

Here you will find Rating & Research studies on HAEMATO AG.

Financial reports

Here you will find the financial figures of the HAEMATO Group in a clear tabular form.

To the Investor Relations Section

Contact

Do you have any questions or suggestions? We look forward to hearing from you.

Privacy Policy

HAEMATO AG

HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany

Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag

 

LINKS

Imprint
Data Protection
Contact

HAEMATO Group

HAEMATO AG
HAEMATO PHARM GmbH
HAEMATO MED GmbH